Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy

Virginie Neirinckx, Hakan Hedman, Simone P. Niclou*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Citations (Scopus)

Abstract

Leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) is an endogenous feedback regulator of receptor tyrosine kinases (RTKs) and was recently shown to inhibit growth of different types of malignancies. Additionally, this multifaceted RTK inhibitor was reported to be a tumor suppressor, a stem cell regulator, and a modulator of different cellular phenotypes. This mini-review provides a concise and up-to-date summary about the known functions of LRIG1 and its related family members, with a special emphasis on underlying molecular mechanisms and the opportunities for harnessing its therapeutic potential against cancer.

Original languageEnglish
Pages (from-to)109-116
Number of pages8
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Volume1868
Issue number1
DOIs
Publication statusPublished - 1 Aug 2017

Keywords

  • Cancer
  • Ectodomain
  • Leucine-rich repeats and immunoglobulin-like domains containing protein 1
  • Nervous system
  • Receptor tyrosine kinase

Fingerprint

Dive into the research topics of 'Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy'. Together they form a unique fingerprint.

Cite this